Chapter 35. Pathogenesis of Microvascular Complications

  1. Richard I. G. Holt MA, MB BChir, PhD, FRCP, FHEA Professor in Diabetes & Endocrinology3,
  2. Clive S. Cockram MB BS, BSc, MD (Lond), FRCP, FRACP, FHKAM (Med) Emeritus Professor of Medicine4,
  3. Allan Flyvbjerg MD, DMSc Professor of Clinical Endocrinology Chair5 and
  4. Barry J. Goldstein MD, PhD, FACP, FACE Therapeutic Area Head Vice President6
  1. Ferdinando Giacco PhD Postdoctoral Fellow1 and
  2. Michael Brownlee MD2

Published Online: 9 JUL 2010

DOI: 10.1002/9781444324808.ch35

Textbook of Diabetes, Fourth Edition

Textbook of Diabetes, Fourth Edition

How to Cite

Giacco, F. and Brownlee, M. (2010) Pathogenesis of Microvascular Complications, in Textbook of Diabetes, Fourth Edition (eds R. I. G. Holt, C. S. Cockram, A. Flyvbjerg and B. J. Goldstein), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444324808.ch35

Editor Information

  1. 3

    Developmental Origins of Health and Disease Division, University of Southampton School of Medicine, Southampton, UK

  2. 4

    Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China

  3. 5

    Department of Endocrinology and Internal Medicine, The Medical Research Laboratories, Aarhus University Hospital – Aarhus University, Aarhus, Denmark

  4. 6

    Clinical Research, Metabolism Merck Research Laboratories Rahway, NJ, USA

Author Information

  1. 1

    Diabetes Research Center, Departments of Medicine and Endocrinology, Albert Einstein College of Medicine, NY, USA

  2. 2

    Anita and Jack Saltz Professor of Diabetes Research, Albert Einstein College of Medicine, New York, NY, USA

Publication History

  1. Published Online: 9 JUL 2010
  2. Published Print: 9 JUL 2010

ISBN Information

Print ISBN: 9781405191814

Online ISBN: 9781444324808

SEARCH

Keywords:

  • Role of hyperglycemia in microvascular complications;
  • Mechanisms of hyperglycemia - induced damage;
  • nicotinic acid adenine dinucleotide phosphate (NADPH);
  • vascular endothelial growth factor (VEGF);
  • Receptor - mediated biologic effects of AGEs;
  • A single process underlying different hyperglycemia - induced pathogenic mechanisms: mitochondrial superoxide production;
  • Hyperglycemia - induced mitochondrial superoxide production inhibits GAPDH by activating poly(ADP - ribose) polymerase;
  • Hyperglycemia - induced mitochondrial superoxide production activates the five damaging pathways by inhibiting GAPDH;
  • Determinants of individual susceptibility to hyperglycemia - induced damage;
  • Potential mechanism - based therapeutic agents for diabetic complications

Summary

This chapter contains sections titled:

  • Overview of diabetic complications

  • Mechanisms of hyperglycemia-induced damage

  • A single process underlying different hyperglycemia-induced pathogenic mechanisms: mitochondrial superoxide production

  • Glycemic memory

  • Determinants of individual susceptibility to hyperglycemia-induced damage

  • Impaired neovascular response to ischemia

  • Hemodynamic factors

  • Potential mechanism-based therapeutic agents for diabetic complications

  • References